Skip to main content
. 2019 Jul 13;14(12):1164–1176. doi: 10.1080/15592294.2019.1640546

Table 1.

Epigenetic compounds approved by Food and Drug Administration (FDA), treatment indication and epigenetic mechanism of action.

FDA approved
Drug (commercial name)		 Year Treatment Mechanism of action Structural formula
Azacitidine+
decitabine or
low-dose cytarabine
(Venclexta)		 2018 Acute myeloid leukemia DNTMi graphic file with name kepi-14-12-1640546-i001.gif
Panobinostat + Bortezomib + Dexamethasone
(Farydak)		 2015 Multiple myeloma HDACi graphic file with name kepi-14-12-1640546-i002.gif
Belinostat
(Belodaq)		 2014 Peripheral T Cells Lymphoma HDACi graphic file with name kepi-14-12-1640546-i003.gif
Valproic Acid 2010 Antidepressive
Neurologic disorders		 HDACi graphic file with name kepi-14-12-1640546-i004.gif
Romidepsin
(Ixodax)		 2009 Cutaneous T-cell lymphoma HDACi graphic file with name kepi-14-12-1640546-i005.gif
5 Azacitidine
(Vidaza)		 2009 Myelodysplastic syndrome DNTMi graphic file with name kepi-14-12-1640546-i006.gif
Vorinostat
(Zolinza)		 2006 Cutaneous T-cell lymphoma HDACi graphic file with name kepi-14-12-1640546-i007.gif

DNMTi, DNA methyltransferase inhibitor; HDACi, Histone desacetilase inhibitor